Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $1.4 million.

  • Gain Therapeutics' Prepaid Assets rose 912.74% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 912.74%. This contributed to the annual value of $945536.0 for FY2024, which is 2749.29% up from last year.
  • As of Q3 2025, Gain Therapeutics' Prepaid Assets stood at $1.4 million, which was up 912.74% from $2.3 million recorded in Q2 2025.
  • Gain Therapeutics' Prepaid Assets' 5-year high stood at $2.3 million during Q2 2025, with a 5-year trough of $550748.0 in Q3 2021.
  • In the last 5 years, Gain Therapeutics' Prepaid Assets had a median value of $954584.0 in 2023 and averaged $1.2 million.
  • In the last 5 years, Gain Therapeutics' Prepaid Assets surged by 26573.21% in 2021 and then tumbled by 4158.34% in 2023.
  • Over the past 5 years, Gain Therapeutics' Prepaid Assets (Quarter) stood at $727785.0 in 2021, then increased by 16.64% to $848854.0 in 2022, then fell by 12.63% to $741638.0 in 2023, then increased by 27.49% to $945536.0 in 2024, then skyrocketed by 52.13% to $1.4 million in 2025.
  • Its Prepaid Assets stands at $1.4 million for Q3 2025, versus $2.3 million for Q2 2025 and $1.8 million for Q1 2025.